---
title: "Cadrenal aligns pipeline into Cardiac Acute Critical Care Franchise, shifts to partnership-driven model"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293338591.md"
description: "Cadrenal Therapeutics reorganized its clinical portfolio into a Cardiac Acute Critical Care Franchise, shifting to a partnership-driven model. The company initiated structured partnering for assets like CAD-1005, frunexian, and tecarfarin, aiming for out-licensing or co-development. This pivot targets capital efficiency and accelerated commercialization with larger partners. Recent Phase 2 data for CAD-1005 showed over a 25% reduction in thrombotic events."
datetime: "2026-07-21T12:06:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293338591.md)
  - [en](https://longbridge.com/en/news/293338591.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293338591.md)
generator: "portal-rs"
---

# Cadrenal aligns pipeline into Cardiac Acute Critical Care Franchise, shifts to partnership-driven model

-   Cadrenal reorganized its clinical portfolio into a Cardiac Acute Critical Care Franchise, shifting focus to late-stage cardiovascular critical care assets. \* Initiated a structured partnering process, targeting out-licensing, portfolio monetization, or co-development deals for CAD-1005, frunexian, tecarfarin. \* Pivoted toward a partnership-driven, capital-efficient operating model to accelerate commercialization with larger industry partners. \* Recast three programs into pre-operative, orphan-pathway, post-operative pillars; CAD-1005 Phase 2 data showed a >25% absolute thrombotic-event reduction. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cadrenal Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607210800PRIMZONEFULLFEED9765377) on July 21, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [CVKD.US](https://longbridge.com/en/quote/CVKD.US.md)

## Related News & Research

- [Cadrenal Therapeutics CEO presents at H.C. Wainwright Global Investment Conference](https://longbridge.com/en/news/297910480.md)
- [10:54 ET/C O R R E C T I O N -- VirtuAlly/](https://longbridge.com/en/news/297669914.md)
- [VivoSim Labs plans rat liver model expansion for NAMkind platform](https://longbridge.com/en/news/297649874.md)
- [Cytosorbents Real-World Data Shows CytoSorb Reduces Severe Bleeding In Cardiac Surgery](https://longbridge.com/en/news/297786128.md)
- [Heartflow FFRCT trial data show 44% drop in unnecessary invasive heart catheterizations](https://longbridge.com/en/news/297276738.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**